OBJECTIVES To assess cost of pharmacotherapy in Polish patients with rheumatoid arthritis (RA) in relation to disease activity (DAS28-CRP) and disability (HAQ-DI). METHODS Data on drug consumption was collected during a prospective one center cohort observational study of non-selected RA patients discharged from tertiary academic hospital. At enrollment patients were divided according to DAS28-CRP and HAQ-DI. Observational period was 6 months. Spearman rang correlation coefficient and test of its significance were used to investigate the relationship of cost of pharmacotherapy with disease activity and disability. Mean total cost of drugs and mean cost of drugs covered by public payer were calculated in PLN at 2014 prices (1 EURO=4.2 PLN in 2014) .   RESULTS DAS28-CRP was ≤5.1 in 124 patients (group A) and >5.1 in 83 patients (group B). HAQ-DI was >2 in 51 patients (group I), >1 and ≤2 in 88 patients (group II), ≤1 in 66 patients (group III). Mean cost of pharmacotherapy per patient was 1010 PLN in group A and 858 PLN in group B, 1078 PLN in group 1, 981 PLN in group II and 745 in group III. The differences between groups were not statistically significant. Public payer covers only 36-40% of the drugs cost. CONCLUSIONS These results represent the current use of drugs in the population of Polish RA patients under real-life conditions and indicate that there is no impact of disease activity and disability on the cost of pharmacotherapy due to RA.